ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. ZetaMet™ is presently i...
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront Deal brings two phase 3 assets in d...
"Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we h...
“We are pleased to announce the closing of this acquisition, as the brands we are adding will strengthen, complement and expand STERIS’s produc...
he three-year agreement includes a joint request to dismiss with prejudice the pending litigation between the companies, including any allegations related ...
Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design and development InstaDeep to opera...
Transaction brings Qunol®, a trusted, profitable double-digit growth and market-leading brand in health & wellness to Sanofi’s CHC U.S. por...
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia Proposed acquisition ...
The partners continue working closely on matters concerning pending approval in the U.S. for AVT02, an interchangeable high-concentration biosimilar candid...
Collaboration Combines ImmunoGen's Proprietary Linker-Payload Technology with Antibodies Developed by ImmunoBiochem Agreement Grants ImmunoGen an Exclusiv...
Endo International plc (OTC: ENDPQ) and Premier, Inc. (NASDAQ: PINC) announced today that Endo's Par Sterile Products business will supply Pitocin® (ox...
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead prog...
Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Bimagrumab...
“We are very pleased with the continued progress being made in our Hansoh Pharma collaboration,” said Craig Tooman, President and CEO of Silenc...
© 2024 Biopharma Boardroom. All Rights Reserved.
